Phase 3 N=77 Decadron as Adjuvant in Femoral Nerve Blocks in Knee Arthroscopy
Knee Injury
Primary: Intra-operative and Post-operative Opioid Consumption — 2; 2; 3 doses
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1 CU Programme of Idarucizumab for Japanese Patients
Hemorrhage
Primary: Percentage of Subjects With Drug-related Adverse Events — 0.0 Percentage of participants
N/A N=40 Assessing the Effectiveness and Safety of the ID-Cap System for Medication Monitoring and Adherence
Medication Adherence
Primary: Medication Adherence — 94.8; 82.8 percentage of doses taken
N/A N=3 Image-Guided Navigation for High Dose Rate Temporary Interstitial Brachytherapy in the Palliative Management of Previously Treated Tumors of the Spine and Pelvis
Metastatic or Recurrent Lesions in the Spine · Metastatic or Recurrent Lesions in the Pelvis
Primary: Maximum Radiation Dose — 7 cord/cauda max dose in Gy
Phase 4 N=186 Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.
Pulmonary Disease, Chronic Obstructive
Primary: Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine L1-L4 — 0.5; 0.2; 0.8; 1.3 Percent Change
Phase 2 N=137 Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants With Serum Testosterone Levels Reduced to ≤ 2 ng/dL After 4 Weeks of Treatment in Japan — 86.0; 100.0 percentage of participants — p=0.1078
Phase 2 N=232 Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Breast Cancer · Neutropenia
Primary: Duration of Moderate Neurtopenia Post First Chemotherapy Administration — 0.6; 0.6; 0.4; 0.3 days
Phase 4 N=318 Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®
Growth Hormone Deficiency · Turner Syndrome
Primary: Change From Baseline in Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) at Month 1 — 1.7692; 1.4007 Standard deviation score (SDS) — p=<0.0001
N/A N=34 Patient Outcomes and Gingival Blood Flow Using Laser Doppler Flowmetry Following the Use of Episil on Free Gingival Graft Donor Sites
Pain From Free Gingival Graft
Primary: Postoperative Pain as Assessed by Number of Participants With a Score of 0-3 (no to Minimal Pain) on a Visual Analog Scale — 12; 6 Participants — p=0.039
Phase 3 N=117 Aim to Reduce Movements in Tardive Dyskinesia
Tardive Dyskinesia
Primary: Change in Centrally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using Mixed Model Repeated Measures (MMRM) Analysis — -3.0; -1.6 units…
N/A N=77 Cognitive Retraining and Brain Stimulation for Alcohol Use
Binge Drinking
Primary: Drinks Per Drinking Day — 6.1; 6.8; 6.6; 7.5 drinks per drinking day
N/A N=29 Effect of Botox and Vibration on Bone in Children With Cerebral Palsy
Cerebral Palsy · Muscle Spasticity
Primary: Bone Structure — 10.4; 7.6; 6.7; 9.0 percent change
Phase 3 N=495 A Study in Adult Patients With Major Depressive Disorder
Depressive Disorder, Major
Primary: Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) at Week 10 — -13.30; -9.82 units on a scale — p=<0.001
Phase 2 N=27 Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer
Colorectal Cancer
Primary: Pathologic Response and Complete Response — 3 Participants
N/A N=40 Depression and ART Adherence in HIV+ Latinos
Depressive Symptoms · HIV Infections
Primary: Depression From (1) Clinician-Administered MADRS Measure, and (2) Participant Self-Report Ratings With BDI-1a — 17.8; 19.2; 19.7; 17.7 Units on a scale